在复杂的PCI后短期DAPT与第三代DES:对HOST-IDEA试验的后期分析
Jung-Kyu Han1,2, Keehwan Lee1,3, Sang-Hyeon Park1,4
1Cardiovascular Center, Seoul National University Hospital, Republic of Korea (J.-K.H., K.L., Sang-Hyeon Park, S.Y., D.H., J.K., H.-M.Y., K.W.P., H.-J.K., B.-K.K., H.-S.K.).
Circulation. Cardiovascular interventions
|March 31, 2025
概括
复杂的穿皮冠状动脉干预 (PCI) 后缩短的双重抗血小板治疗 (DAPT) 可以降低出血风险,而不会增加缺血事件. 这一发现支持使用药物释放支架的复杂PCI患者的3至6个月DAPT持续时间.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复杂的穿皮冠状动脉干预 (PCI) 后,双重抗血小板治疗 (DAPT) 的最佳持续时间尚未得到充分确立.
- 复杂的PCI涉及诸如多种支架植入,广泛的损伤治疗或左主干预等程序.
- 接受复杂PCI的患者往往会出现更高的出血风险,因此需要仔细考虑DAPT的持续时间.
研究的目的:
- 在复杂的PCI后,与标准的12个月持续时间相比,缩短DAPT持续时间 (3-6个月) 的疗效和安全性进行评估.
- 为了确定较短的DAPT疗程是否会影响缺血事件 (目标病变失败) 和出血事件 (严重出血) 的风险.
主要方法:
- 对HOST-IDEA随机试验的后期分析,该试验涉及使用第三代药物释放支架治疗的患者.
- 复杂的PCI是由特定的程序标准定义的,包括支架数量,治疗的病变,支架长度和解剖复杂性.
- 主要终点包括12个月的目标病变衰竭 (心脏死亡,心肌梗塞,再血管) 和严重出血 (BARC型3或5).
主要成果:
- 在复杂的PCI子组 (n=624) 中,3至6个月的DAPT持续时间没有增加目标病变失效的风险 (HR 0.818).
- 缩短的DAPT显著降低了复杂PCI组严重出血的风险 (HR 0.269,P相互作用=0.029).
- 在非复杂的PCI组与缩短的DAPT中没有观察到缺血事件的显著增加或出血的显著减少.
结论:
- 3至6个月的DAPT持续时间对于接受复杂PCI的患者,使用第三代药物排泄支架,是安全有效的.
- 在这个人群中缩短DAPT可以减少出血并发症,而不会影响缺血的结果.
- 这些发现提供了根据PCI复杂性量身定制DAPT持续时间的证据.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
448
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
448
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
01:26Peptic Ulcer Disease IV: Management
57
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
57
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
879
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
879